A UK report has said that inflation and geopolitical instability have led to a “dramatic drop” in investment in smaller companies developing new medicines, with a knock-on
It has been more than four years since the UK left the EU, but the government is still being forced to delay the introduction of border control rules that could have conse
The first quarter of 2023 saw just £295 million raised by UK-based life sciences and biotech companies, signalling that investor confidence remains low after a disappointi
2021 was a record year for investments in UK biotech companies, consolidating the country's position as one of Europe's top life science hubs and apparently shrugging off the effects of the
There has been a well-publicised boom in biotech investment during the pandemic, and the UK is no exception, with a record £1 billion raised in the third quarter.
AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceut